Kintor Pharmaceutical Limited (9939)

Overview

Kintor Pharmaceutical Limited is a clinical-stage biotechnology firm that focuses on the development and commercialization of innovative therapeutic solutions for diseases related to the androgen receptor, addressing areas where medical needs remain unmet. Operating out of the People's Republic of China and extending its reach internationally, Kintor aims to pioneer treatments in several therapeutic areas. Established in 2009 and with its headquarters in Suzhou, China, the company leverages a deep understanding of androgen-receptor-related diseases to bring forward novel treatments that aim to improve the lives of patients worldwide.

Products and Services

Listed below are the key products and services offered by Kintor Pharmaceutical Limited, each aiming to target critical and often hard-to-treat conditions:

• Proxalutamide: A second-generation androgen receptor (AR) antagonist designed for the treatment of metastatic castration-resistant prostate cancer, AR-positive breast cancer, and also explored for treating COVID-19. Proxalutamide represents Kintor's commitment to addressing resistant forms of cancer and emerging health challenges.
• Pyrilutamide: This product targets androgenetic alopecia (AGA) and acne vulgaris through antagonism of the androgen receptor. Pyrilutamide's development underlines the company's focus on both significant and common dermatological conditions, providing potential relief for millions affected by these issues.
• ALK-1 Antibody: Geared towards the treatment of metastatic hepatocellular carcinoma (HCC) and various solid tumors, the ALK-1 antibody aims at inhibiting specific pathways to prevent cancer progression. Its target of solid tumors and HCC highlights the broad applicability of Kintor's research in oncology.
• GT20029: A topical AR-PROTAC compound being developed for the treatment of androgenetic alopecia and acne vulgaris. As a topical solution, GT20029 represents an innovative approach in Kintor's pipeline, showing the company's versatility in drug formulation and delivery methods.
• PD-L1/TGF-ß Dual Target Antibody: This dual-target antibody is designed for the treatment of non-small cell lung cancer, biliary tract cancer, triple-negative breast cancer, and HPV-associated tumors. By targeting PD-L1 and TGF-ß, it embodies a cutting-edge approach to cancer therapy, reflecting the innovative spirit of Kintor Pharmaceutical.
• Detorsertib: A kinase inhibitor tailored for the treatment of metastatic solid tumors such as breast cancer, prostate cancer, and HCC. Detorsertib represents a critical component of Kintor's focus on solid tumor cancers, offering potential new therapies to patients with these challenging conditions.
• Hedgehog/SMO Inhibitor: This inhibitor targets the hedgehog signaling pathway, which is crucial in the development of blood cancer. The Hedgehog/SMO Inhibitor is part of Kintor's diverse oncology portfolio, aimed at novel targets to treat cancer more effectively.